CKPT: Rasio kapitalisasi pasar marang pendapatan Checkpoint Therapeutics Inc.
Checkpoint Therapeutics (CKPT) maintains a strong R&D center, attracting leading experts through a stock option system. The price/sales multiple reflects the valuation trend, with the indicator holding at 9239.00. The biotech startup is implementing affordable targeted therapy methods. The strategy is based on reducing development costs for cosibelimab, enabling the company to offer effective skin cancer treatment at a competitive price.
Rincian metrik lan analitis perusahaan Checkpoint Therapeutics, Inc (CKPT)
- rega pasar lan target rega analis:
- informasi kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Checkpoint Therapeutics|CKPT - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang ekuitas Checkpoint Therapeutics Inc|CKPT - Utang perusahaan|Utang-utang marang nilai buku Checkpoint Therapeutics, Inc|CKPT - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Checkpoint Therapeutics|Rasio likuiditas darurat checkpointtx.com
- data bathi lan kelipatan valuasi:
CKPT - Penghasilan resik|Bathi resik mangsa ngarep Checkpoint Therapeutics|CKPT - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Checkpoint Therapeutics Inc.|CKPT - Pangali rega marang bathi tumrap wutah|Koefisien nilai perusahaan marang bathi operasional sadurunge panyusutan Checkpoint Therapeutics, Inc|CKPT - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Checkpoint Therapeutics|CKPT - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan checkpointtx.com|CKPT - Wutah bathi saben saham ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Checkpoint Therapeutics
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:CKPT - checkpointtx.com
Checkpoint Therapeutics operates within an autonomous drug development cycle, where the demand for medical innovation renders the business resilient to global macroeconomic shocks. By analyzing the price-to-sales trend, an investor assesses the ratio of market capitalization to annual sales volume, which allows for the determination of the asset's overvaluation or the business's growth potential based on current revenue generation rates.
Perusahaan pesaing
Kapitalisasi marang pendapatan beigene.com ONC|Multiplikator P/S HALO (Halozyme)|Rasio kapitalisasi pasar marang pendapatan RVMD|Ascentage - Multiplikator P/S|Rega marang dodolan CG Oncology Therapeutics|URGN: Multiplikator P/S|Kapitalisasi marang pendapatan bicara.com|Rasio rega marang pendapatan Personalis|Multiplikator P/S Erasca Inc|Rasio rega marang pendapatan Delcath (DCTH)|YMAB: Rasio rega marang dodolan|Rasio rega marang pendapatan Aura Biosciences, Inc. AURA|Candel Therapeutics Inc. (CADL) - Rega marang dodolan|Accuray - Multiplikator P/S|Koefisien rega marang pendapatan SELLAS Life Sciences SLS|Actuate Therapeutics, Inc (ACTU) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan CTOR|Kapitalisasi marang pendapatan HURA|TARA (protaratx.com) - Kapitalisasi marang volume dodolan|Kapitalisasi marang pendapatan FATE (Fate Therapeutics)|WHWK (aadibio.com) - Rasio kapitalisasi pasar marang pendapatan|TScan Therapeutics, Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan CSBR (Champions Oncology Inc)|XBiotech USA - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan CVM (CEL-SCI Corporation)|OSTX: Multiplikator P/S|Rega marang dodolan radiopharmtheranostics.com (RADX)|Rasio rega marang pendapatan Artiva Biotherapeutics Inc.|ANL: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S VERU|Multiplikator P/S tempesttx.com (TPST)|Rasio rega marang pendapatan Xilio Therapeutics XLO|RENB (Renovaro Biosciences) - Rasio rega marang dodolan|Mural Bio - Multiplikator P/S|Rega marang dodolan Kairos Pharma Ltd|OKUR (onkuretherapeutics.com) - Kapitalisasi marang pendapatan|CytoMed Therapeutics Limited (GDTC) - Multiplikator P/S|Kapitalisasi marang pendapatan CRIS|APLM (Apollomics Corp) - Kapitalisasi marang volume dodolan|Multiplikator P/S THAR|Koefisien rega marang pendapatan advanbiomed.com|Multiplikator P/S GNPX (Genprex, Inc.)|CLDI - Kapitalisasi marang pendapatan|SBFM - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Xenetic Biosciences XBIO|SLRX: Multiplikator P/S|Kapitalisasi marang pendapatan Kitov Pharma|Rasio rega marang pendapatan American Oncology Network Inc|Multiplikator P/S beigene.com|Rasio rega marang pendapatan Elevation Oncology (ELEV)|ICAD: Rasio rega marang dodolan|Ikena Oncology - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan NTBL (Notable Labs Corp)|Viracta - Multiplikator P/S|morphosys.com (MOR) - Kapitalisasi marang pendapatan|NAYA: Multiplikator P/S|Ascentage Pharma Group International (AAPGV) - Multiplikator P/S
